Mr. Seelye will help to strengthen our technology and data strategy, leading the development of key products and services designed to transform the customer experience. SAN DIEGO, March 30, 2020— Progenity, a biotechnology company with an established track record of success in developing and

Our lab is fully operational and we are offering assisted patient education and collection services to support healthcare providers and patients. Recent public health measures related to the novel coronavirus are greatly impacting healthcare practices.

We will present results from clinical laboratory experience that indicate noninvasive prenatal testing (NIPT) performs well for predicting aneuploidies in twin pregnancies. SAN DIEGO – February 5, 2020  – Progenity, developing precision medicine solutions across genomic/epigenomic, proteomic, and

Highlighting our work to improve the diagnosis and management of patients with small intestinal bacterial overgrowth (SIBO). Progenity was featured in  Gastroenterology & Endoscopy News  for our work on a capsule that improves the diagnosis and management of patients with small intestinal bacterial

SAN DIEGO and DANVILLE, Pa.  – December 10, 2019 – Progenity, a privately held biotechnology company, and  Geisinger , one of the nation’s most innovative health services organizations, announced publication of a study in  Obstetrics & Gynecology  demonstrating the significant economic burden

SAN DIEGO, November 19, 2019  – Progenity, Inc. announced today that we'll be participating in the Piper Jaffray 31st Annual Healthcare Conference in New York, December 3 – 5. Progenity’s chief executive officer, Harry Stylli, PhD, will present a corporate overview on Wednesday, December 4, from

Highlighting Opportunities for Technologies Aimed at Improving Diagnosis and Treatment of Gastrointestinal Disorders SAN DIEGO, October 29, 2019  – Progenity, Inc., a privately held biotechnology company, presented three posters this week at the 2019 American College of Gastroenterology Annual

SAN DIEGO, October 22, 2019  – Progenity, Inc., a privately held biotechnology company developing precision medicine solutions across genomic/epigenomic, proteomic, and microbiomic diagnostic and therapeutic platforms, announced the promotion of Sami Shihabi to chief commercial officer.

This acquisition further strengthens Progenity’s existing intellectual property portfolio and development of ingestible devices designed to advance research, diagnosis, and treatment for conditions of the gastrointestinal (GI) tract. SAN DIEGO, September 18, 2019  – Progenity, Inc., a privately

Dr. Kotzin’s experience in the development of novel biotherapeutics, especially in autoimmune and inflammatory diseases, will provide valuable guidance as the company advances its pipeline of precision therapeutics/biotherapeutics and diagnostics. SAN DIEGO, August 7, 2019  – Progenity, Inc., a